The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia

Schizophrenia Research

Volumn 59, Issue 1, 2003, Pages 7-16

  Sumiyoshi, Tomiki ^a   Jayathilake, Karu ^a   Meltzer, Herbert Y ^a  

^a Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Atypical antipsychotic drug; Cognition; Executive function; Melperone; Quality of life; Schizophrenia; Social function

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; MELPERONE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPTH PERCEPTION; DRUG EFFECT; DRUG RESISTANCE; FEMALE; HUMAN; INTELLIGENCE; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL STATUS; TREATMENT OUTCOME; WORK;

ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; COGNITION; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; SCHIZOPHRENIA;

EID: 0037210024     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(01)00329-2     Document Type: Article

References (61)

1. Addington J., Addington D. Neurocognitive and social functioning in schizophrenia. Schizophr. Bull. 25:1999;173-182.
2. Addington J., Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr. Res. 44:2000;47-56.
3. Addington J., Addington D., Gasbarre L. Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophr. Res. 48:2001;367-368.
4. American Psychiatric Association DSM-III-R: Diagnostic and Statistical Manual of Mental Disorders, 3rd edn., Rev. 1987;American Psychiatric Association, Washighton, DC.
5. Barbato L., Monge A., Stocchi F., Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct. Neurol. 11:1996;201-207.
6. Bergman A.J., Harvey P.D., Roitman S.L., Mohs R.C., Marder D., Silverman J.M., Siever L.J. Verbal learning and memory in schizotypal personality disorder. Schizophr. Bull. 24:1998;635-641.
7. Bjerkenstedt L. Melperone in the treatment of schizophrenia. Acta Psychiatr. Scand., Suppl. 352:1989;35-39.
8. Bjerkenstedt L., Harnryd C., Grimm V., Gullberg B., Sedvall G. A double-blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch. Psychiatr. Nervenkrankh. 226:1978;157-172.
9. Buchanan R.W., Holstein C., Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol. Psychiatry. 36:1994;717-725.
10. Cadenhead K.S., Perry W., Shafer K., Braff D.L. Cognitive functions in schizotypal personality disorder. Schizophr. Res. 37:1999;123-132.
11. Christensen I., Geismar L., Kirkegaard A., Kirkegaard G. Additional studies on side effects of melperone in long-term therapy for 1-20 years in psychiatric patients. Arzneim.-Forsch. 36:1986;855-860.
12. Cuesta M.J., Peralta V., Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr. Res. 48:2001;17-28.
13. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorder and schizophrenia. Arch. Gen. Psychiatry. 35:1978;837-844.
14. Galletly C.A., Clark C.R., McFarlane A.C., Weber D.L. Relationships between changes in symptom ratings, neurophysiological test performance and quality of life in schizophrenic patients treated with clozapine. Psychiatry Res. 72:1997;161-166.
15. Gallhofer B., Bauer U., Lis S., Krieger S., Gruppe H. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur. Neuropsychopharmacol. 6:1996;S13-S20.
16. Goldberg T.E., Greenberg R.D., Griffin S.J., Gold J.M., Kleinman J.E., Pickar D., Schulz S.C., Weinberger D.R. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br. J. Psychiatry. 162:1993;43-48.
17. Gooding D.C., Kwapil T.R., Tallent K.A. Wisconsin Card Sorting Test deficits in schizotypic individuals. Schizophr. Res. 40:1999;201-209.
18. Green M.F., Marshall B.D. Jr., Wirshing W.C., Ames D., Marder S.R., McGurk S., Kern R.S., Mintz J. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am. J. Psychiatry. 154:1997;799-804.
19. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr. Bull. 26:2000;119-136.
20. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol. Psychiatry. 34:1993;702-712.
21. Harnryd C., Bjerkenstedt L., Gullberg B. A clinical comparison of melperone and placebo in schizophrenic women on a milieu therapeutic ward. Acta Psychiatr. Scand., Suppl. 352:1989;40-47.
22. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry. 58:2001;24-32.
23. Hoff A.L., Faustman W.O., Wieneke M., Espinoza S., Costa M., Wolkowitz O., Csernansky J.G. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 15:1996;361-369.
24. Ichikawa J., O'Laughlin I.A., Dai J., Fowler W.L., Meltzer H.Y. Clozapine increased extracellular acetylcholine (Ach-ext) levels in rat medial prefrontal cortex but not striatum or nucleus accumbens in the absence of Ach-esterase inhibition. Soc. Neurosci. Abstr. 25(Pt. 1):1999;452.
25. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
26. Kawasaki Y., Maeda Y., Suzuki M., Urata K., Higashima M., Kiba K., Yamaguchi N., Matsuda H., Hisada K. SPECT analysis of regional cerebral blood flow changes in patients with schizophrenia during the Wisconsin Card Sorting Test. Schizophr. Res. 10:1993;109-116.
27. Keefe R.S.E., Silva S.G., Perkins D.O., Lieberman J.A. The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr. Bull. 25:1999;201-222.
28. Kenny J.T., Meltzer H.Y. Attention and higher cortical functions in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 3:1991;269-275.
29. Kern R.S., Green M.F., Marshall B.D. Jr., Wirshing W.C., Wirshing D., McGurk S.R., Marder S.R., Mintz J. Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr. Bull. 25:1999;223-232.
30. Kirkegaard A., Kirkegaard G., Geismar L., Christensen I. Additional studies on side effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients. Arzneim.-Forsch. 31:1981;737-740.
31. Koyama T., Nakajima Y., Fujii T., Kawashima K. Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAYx3702 in freely moving rats. Neurosci. Lett. 265:1999;33-36.
32. Kuroki H., Meltzer H.Y., Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontalcortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1998;774-781.
33. Lee M.A., Thompson P.A., Meltzer H.Y. Effects of clozapine on cognitive function in schizophrenia. J. Clin. Psychiatry. 55:1994;82-87.
34. Lee M.A., Jayathilake K., Meltzer H.Y. A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr. Res. 37:1999;1-11.
35. Lindenmayer J.P., Iskander A., Park M., Apergi F.S., Czobor P., Smith R., Allen D. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J. Clin. Psychiatry. 59:1998;521-527.
36. Marenco S., Coppola R., Daniel D.G., Zigun J.R., Weinberger D.R. Regional cerebral blood flow during the Wisconsin Card Sorting Test in normal subjects studied by xenon-133 dynamic SPECT: comparison of absolute values, percent distribution values, and covariance analysis. Psychiatry Res. 50:1993;177-192.
37. McGurk S.R., Meltzer H.Y. The role of cognition in vocational functioning in schizophrenia. [In Process Citation] Schizophr. Res. 45:2000;175-184.
38. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
39. Meltzer H.Y., Fang V.S., Young M.A. Clozapine-like drugs. Psychopharmacol. Bull. 16:1980;32-35.
40. Meltzer H.Y., Alphs L.D., Bastani B., Ramirez L. Effect of melperone in treatment-resistant schizophrenia. Stefanis C.N., Soldatos C.R., Rabavilas A.D. VIII World Congress of Psychiatry Abstracts. vol. 899:1989;502 Excerpta Medica, Amsterdam.
41. Meltzer H.Y., Thompson P.A., Lee M.A., Ranjan R. Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology. 14:1996;27S-33S.
42. Meltzer H.Y., O'Laughlin I.A., Dai J., Fowler W.L., Ichikawa J. Atypical antipsychotic drugs (APD) but not typical APD increased extracellular acetylcholine (Ach-ext) levels in rat medialprefrontal cortex in the absence of Achesterase (AchE) inhibition. Soc. Neurosci. Abstr. 25(Pt. 1):1999;452.
43. Norman R.M., Malla A.K., Cortese L., Cheng S., Diaz K., Macintosh E., McLean T.S., Rickwood A., Voruganti L.P. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am. J. Psychiatry. 156:1999;400-405.
44. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature. 385:1997;634-636.
45. Overall J.E., Gorham D.R. The brief psychiatric rating scale. Psychol. Rep. 10:1962;799-812.
46. Parada M.A., Hernandez L., Puig de Parada M., Rada P., Murzi E. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum. J. Pharmacol. Exp. Ther. 281:1997;582-588.
47. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br. J. Psychiatry. 166:1995;712-726. discussion 727-733.
48. Purdon S.E., Jones B.D., Stip E., Labelle A., Addington D., David S.R., Breier A., Tollefson G.D. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch. Gen. Psychiatry. 57:2000;249-258.
49. Purdon S.E., Labelle A., Boulay L. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr. Res. 48:2001;57-67.
50. Rasmusson A.M., Goldstein L.E., Deutch A.Y., Bunney B.S., Roth R.H. 5-HT1a agonist ±8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse. 18:1994;218-224.
51. Rossi A., Mancini F., Stratta P., Mattei P., Gismondi R., Pozzi F., Casacchia M. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta Psychiatr. Scand. 95:1997;40-43.
52. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br. J. Psychiatry. 174:1999;44-51.
53. Sharma T., Harvey P. Cognition in Schizophrenia: Impairments, Importance and Treatment Strategies. 2000;Oxford Univ. Press, New York.
54. Sharma T., Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. J. Clin. Psychopharmacol. 18:1998;12S-19S.
55. Stratta P., Daneluzzo E., Bustini M., Prosperini P., Rossi A. Processing of context information in schizophrenia: relation to clinical symptoms and WCST performance. Schizophr. Res. 44:2000;57-67.
56. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Prediction of short-term changes in symptom severity by baseline plasma homovanillic acid levels in schizophrenic patients receiving clozapine. Psychiatry Res. 69:1997;113-121.
57. Sumiyoshi T., Hasegawa M., Jayathilake K., Meltzer H.Y. Sex differences in plasma homovanillic acid levels in schizophrenia and normal controls: relation to neuroleptic resistance. Biol. Psychiatry. 41:1997;560-566.
58. Sumiyoshi T., Kurachi M., Kurokawa K., Yotsutsuji T., Uehara T., Itoh H., Saitoh O. Plasma homovanillic acid in the prodromal phase of schizophrenia. Biol. Psychiatry. 47:2000;428-433.
59. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., Meltzer H.Y. Enhancement of cognitive performance in schizophrenia by the addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry. 158:2001;1722-1725.
60. Toone B.K., Okocha C.I., Sivakumar K., Syed G.M. Changes in regional cerebral blood flow due to cognitive activation among patients with schizophrenia. Br. J. Psychiatry. 177:2000;222-228.
61. Tsai G., Yang P., Chung L.C., Lange N., Coyle J.T. D-serine added to antipsychotics for the treatment of schizophrenia. Biol. Psychiatry. 44:1998;1081-1089.